| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 05/30/2001 | EP1102743A1 Amide derivatives which are useful as cytokine inhibitors |
| 05/30/2001 | EP1102739A1 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
| 05/30/2001 | EP1102599A1 Protease inhibitors for use in the treatment of psoriasis |
| 05/30/2001 | EP1102598A1 Hair growth/maintenance compositions and methods involving the same |
| 05/30/2001 | EP1102597A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht 4 receptors |
| 05/30/2001 | EP1102584A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 05/30/2001 | EP1102535A2 Compounds and methods |
| 05/30/2001 | EP0730607B1 Novel integrin-binding peptides |
| 05/30/2001 | CN1297356A Matrix protein compositions for wound healing |
| 05/30/2001 | CN1297354A Dipeptide caspase inhibitors and use thereof |
| 05/30/2001 | CN1297344A Method and compositions for in situ formation of protective and/or medicated film on body tissue |
| 05/30/2001 | CN1296852A Chitosan/gelatin network modification on surface of aliphatic polyester |
| 05/30/2001 | CN1296850A Formulations of 23 medicines |
| 05/30/2001 | CN1296832A Chinese medicine for treating psoriasis |
| 05/30/2001 | CN1296817A Exterior-applied liquid medicine for treating acne |
| 05/29/2001 | US6239288 Biphenyl hydroxy imino butyric acids and their derivatives for treating arthritis |
| 05/29/2001 | US6239284 Skin disorders; anticancer agents |
| 05/29/2001 | US6239176 Administering to treat blood disorders like anemia; wound healing, anticarcinogenic and antiproliferative agents; genetic disorders |
| 05/29/2001 | US6239173 Antiinflammatory, antipyretic, analgesic, and antiarthritic agents |
| 05/29/2001 | US6239170 Applying 5-lipoxygenase inhibitor |
| 05/29/2001 | US6239164 Immunophilin affinity; nonimmunosuppressant |
| 05/29/2001 | US6239147 To treat cns, gastrointestinal and other disorders. substance p antagonists having improved activity and fewer side effects, treatment of emesis induced by antineoplastic agents, isochroman ring |
| 05/29/2001 | US6239138 Vitronectin receptor antagonist |
| 05/29/2001 | US6239137 Salts of aminoimidazole carboxamide and 5 amino or substituted amino 1,2,3-triazole, induce apoptosis, inhibit DNA synthesis and control cyclooxygenase activity |
| 05/29/2001 | US6239130 Phosphodiesterase 4-inhibiting diazepinoindolones |
| 05/29/2001 | US6239124 Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
| 05/29/2001 | US6239116 Immunostimulatory nucleic acid molecules |
| 05/29/2001 | US6239102 Concentrate comprising, as active agent, (3'-desoxy-3-oxo-mebmc)1-(val)2-cyclosporin, stabilizer selected from oleic acid or palmitoyl oleoyl phosphatidyl glycerol or salts thereof, ethanol |
| 05/29/2001 | US6238921 Antisense oligonucleotide modulation of human mdm2 expression |
| 05/29/2001 | US6238900 Nucleotide sequence coding enzymatic polypeptide; for the prevention of bacterial infections; bactericides |
| 05/29/2001 | US6238888 Keratinocyte growth factor-2 formulations |
| 05/29/2001 | US6238681 Single-phase transparent aqueous cosmetic composition |
| 05/29/2001 | US6238674 Use of an extract of Cordia dichotoma |
| 05/29/2001 | US6238663 Irradiating with light |
| 05/29/2001 | US6238650 Said sunscreen active ingredient is in the form of sol-gel microcapsules containing at least one sunscreen compound. |
| 05/29/2001 | US6238645 Methods of oxygenating tissues |
| 05/29/2001 | CA2325778A1 Use of 1,1-dioxoperhydro-1,2,4-thiadiazines |
| 05/29/2001 | CA2195923C Azetidines |
| 05/29/2001 | CA2019273C Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| 05/25/2001 | WO2001036645A2 Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same |
| 05/25/2001 | WO2001036642A1 HUMAN MONOCLONAL ANTIBODIES AGAINST TGF-βII RECEPTOR AND MEDICINAL USE THEREOF |
| 05/25/2001 | WO2001036630A2 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
| 05/25/2001 | WO2001036604A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 05/25/2001 | WO2001036487A2 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/25/2001 | WO2001036462A2 Protein c derivatives |
| 05/25/2001 | WO2001036454A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 05/25/2001 | WO2001036451A1 Vitamin e derivatives |
| 05/25/2001 | WO2001036440A1 23 human secreted proteins |
| 05/25/2001 | WO2001036425A2 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 05/25/2001 | WO2001036422A1 Tricyclic dihydropyrimidine potassium channel openers |
| 05/25/2001 | WO2001036420A1 Tricyclic azaindolizine derivatives having an spla2- inhibiting effect |
| 05/25/2001 | WO2001036403A1 Urea derivatives as anti-inflammatory agents |
| 05/25/2001 | WO2001036398A1 Benzoxa- and benzthiazoles |
| 05/25/2001 | WO2001036395A1 Triazoles as farnesyl transferase inhibitors |
| 05/25/2001 | WO2001036376A1 Novel phenylalanine derivatives |
| 05/25/2001 | WO2001036374A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments |
| 05/25/2001 | WO2001036005A2 Targeted delivery of therapeutic and diagnostic moieties |
| 05/25/2001 | WO2001035971A1 Whitening compositions for oral administration |
| 05/25/2001 | WO2001035966A1 Boron compounds and complexes as anti-inflammatory agents |
| 05/25/2001 | WO2001035960A1 Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases |
| 05/25/2001 | WO2001035943A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 05/25/2001 | WO2001035936A2 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases |
| 05/25/2001 | WO2001035933A2 A method of microencapsulation |
| 05/25/2001 | WO2001035920A1 Cosmetic compositions containing chick pea extract and retinoids |
| 05/25/2001 | WO2001035914A1 Use of nonimmunosuppressive cyclosporin derivatives for hair growth |
| 05/25/2001 | WO2001035906A2 Personal care articles comprising a hydrophilic conditioning agent exhibiting a defined leaching value |
| 05/25/2001 | WO2001035905A2 Personal care articles comprising cationic polymer coacervate compositions |
| 05/25/2001 | WO2001035901A2 Use of enzymes for skin expansion |
| 05/25/2001 | WO2001005942A3 Improved keratinocyte culture and uses thereof |
| 05/25/2001 | WO2001005362A3 Emulsifier-free finely dispersed water-in-oil-type systems |
| 05/25/2001 | WO2000078330A3 Adenosine diphosphatase and activators thereof and their medical uses |
| 05/25/2001 | CA2396428A1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/25/2001 | CA2391908A1 Novel polypeptides and nucleic acids encoding same |
| 05/25/2001 | CA2391651A1 Protein c derivatives |
| 05/25/2001 | CA2391603A1 Cosmetic compositions containing chick pea extract and retinoids |
| 05/25/2001 | CA2391450A1 Targeted delivery of therapeutic and diagnostic moieties |
| 05/25/2001 | CA2391291A1 Tricyclic dihydropyrimidine potassium channel openers |
| 05/25/2001 | CA2391087A1 Imidazole compounds as phosphodiesterase vii inhibitors |
| 05/25/2001 | CA2391039A1 Personal care articles comprising a hydrophilic conditioning agent exhibiting a defined leaching value |
| 05/25/2001 | CA2391032A1 Personal care articles comprising cationic polymer coacervate compositions |
| 05/25/2001 | CA2389862A1 Human monoclonal antibody against tgf-.beta.ii receptor and medicinal use thereof |
| 05/25/2001 | CA2388922A1 23 human secreted proteins |
| 05/24/2001 | US20010001790 Topical formulations comprising skin penetration agents and the use thereof |
| 05/24/2001 | US20010001783 Retinol stabilized cleansing compositions |
| 05/24/2001 | US20010001667 Oil in water(O/W); oily phase dispersed in aqueous phase, containing at least one anionic emulsifier which is liquid at room temperature, and the oily phase is in the form of a soft paste at room temperature; minimizing wrinkles, dry skin |
| 05/23/2001 | EP1101757A1 Heterocyclic compounds as tachykinin receptor antagonists |
| 05/23/2001 | EP1101494A1 Composicion para la estimulacion de la sintesis del pigmento melanico y procedimiento para su obtencion |
| 05/23/2001 | EP1100964A1 Gene sequence variances with utility in determining the treatment of disease |
| 05/23/2001 | EP1100913A1 Mekk1 serine threonine kinases -interacting fha forkhead associated domain protein 1 (mif1) |
| 05/23/2001 | EP1100909A2 Dna replication- and repair-associated proteins |
| 05/23/2001 | EP1100908A2 Human receptor-associated proteins |
| 05/23/2001 | EP1100907A2 Human cytoskeletal proteins |
| 05/23/2001 | EP1100894A2 Short oligonucleotides for the inhibition of vegf expression |
| 05/23/2001 | EP1100882A1 Human protein kinase h2lau20 |
| 05/23/2001 | EP1100869A1 98 human secreted proteins |
| 05/23/2001 | EP1100829A2 Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases |
| 05/23/2001 | EP1100822A1 Secreted cysteine rich protein-6 (scrp-6) |
| 05/23/2001 | EP1100814A2 Inhibitors of urokinase and blood vessel formation |
| 05/23/2001 | EP1100808A1 Prostate derived ets factor |
| 05/23/2001 | EP1100807A1 STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |